Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Ohalo develops products aimed at improving agricultural productivity and supporting farmers globally. Founded in 2019, the company works in the agriculture technology and genetics space.
2 investors
Okomera builds a platform combining miniaturized tumor-on-chip technology and AI imaging to analyze patient-derived biopsies and predict personalized drug response for cancer treatment. Its tools serve clinicians and drug developers, spanning drug development to clinical decision-making.
2 investors
OlsAro develops climate-resilient cereal crops through gene editing and breeding technologies to improve crop yields and food security. The company partners with seed companies to commercialize traits that help farmers adapt to challenging environmental conditions like saline soils.
2 investors
OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases. Its lead candidate OMT-28 is in Phase 2 clinical trials for conditions including atrial fibrillation and primary mitochondrial disease; the company was spun out of the Max DelbrΓΌck Center for Molecular Medicine in Berlin.
2 investors
Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications. The company pursues orphan, large-market, and novel therapeutic programs through vertically integrated drug development.
2 investors
Vedaly provides AI, data analytics, and decision support tools for biopharma companies to integrate insights into scientific and strategic planning. The platform helps pharmaceutical and biotech teams move faster and make data-driven decisions across drug development and research.
2 investors
Omnix Medical is a biopharmaceutical company founded in 2015 that develops novel antibiotic agents to treat infections caused by drug-resistant bacteria. Its lead compound, OMN6, is a first-in-class antimicrobial in Phase II clinical trials targeting drug-resistant Acinetobacter baumannii infections.
2 investors
2 investors
Oncimmune is a biomarker discovery and diagnostics company specializing in proteomics and bioinformatics technologies for autoimmunity, cancer research, and clinical drug development. The company serves pharmaceutical, biotech, and academic partners by developing diagnostic tools and biomarkers for various phases of clinical development.
2 investors
Oncoinvent is a biotechnology company focused on drug development and commercialization in the pharmaceutical sector. The company is led by executives with extensive experience in biotech management, clinical programs, and global pharmaceutical commercialization.
2 investors
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.
2 investors
OncoHost develops the PROphet platform, a precision medicine diagnostic tool combining proteomics, bioinformatics, and machine learning to help oncologists predict patient response to cancer therapies and select optimal treatment. The company serves clinicians and cancer patients worldwide with biomarker-driven insights to overcome treatment resistance.
2 investors
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
2 investors
Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease. It operates a capital-efficient model, retaining regional development rights while forming strategic partnerships, and collaborates with patient communities in the rare disease space.
2 investors
OncoPatch develops a non-invasive medical patch that delivers low-energy beta therapy to treat non-melanoma skin cancers, including basal and squamous cell carcinomas. The single-application treatment is administered in a physician's office and targets cancer cells while sparing healthy tissue.
2 investors
Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine). The company targets an orphan drug indication with clinical development underway.
2 investors
OneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development. The platform delivers tumor intelligence reports with functional signatures for precision oncology within two weeks.
2 investors
OnePot is a tool for synthesizing molecules, with end-to-end encryption of users' molecular structures. It appears aimed at chemistry and drug discovery users who require confidentiality of their chemical data.
2 investors
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3KΞ± pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
2 investors
ONTOFORCE provides data science solutions and support services centered around DISQOVER, guiding customers through implementation, customization, and ongoing support to meet their specific needs.
2 investors
ONWARD Health Research is a technology and services company offering tech-enabled clinical trials through its ONWARDAccess platform, which is customized to match clinical trial protocols. It serves the pharma/biotech, medical device, and digital health sectors, with a focus on the Asia-Pacific region.
2 investors
Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. It is building a pipeline of disease-modifying and symptomatic treatments for neurodegenerative diseases, including Huntington's disease and cognition-related conditions.
2 investors
2 investors
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
2 investors